There is no public confirmation of a direct family, personal, employment or business relationship between Miguel Patricio and Albert Bourla. The strongest documented connection is narrower: both became chief executives of major U.S.-listed companies in 2019 and were included in Feigen Advisors’ S&P 250 New CEO Class of 2019.
Their careers otherwise developed along very different paths. Patricio built his reputation in consumer products, beverages and global marketing before becoming CEO of Kraft Heinz. Bourla trained as a veterinarian, spent decades inside Pfizer and rose through pharmaceutical and scientific leadership to become the company’s chairman and CEO.
As of October 2, 2026, Patricio serves on the board of Anheuser-Busch InBev as a representative of its main shareholders, while Bourla remains Pfizer’s Chairman and Chief Executive Officer.
What connects Miguel Patricio and Albert Bourla?
The most concrete connection is timing rather than collaboration.
Pfizer announced in October 2018 that Bourla would become CEO effective January 1, 2019, succeeding Ian Read. The company described Bourla as a long-serving Pfizer executive who had most recently been chief operating officer. Pfizer’s CEO succession announcement records that transition.
Patricio arrived at Kraft Heinz later the same year. Kraft Heinz initially announced a July 1, 2019 start, but an SEC filing later recorded that his appointment was accelerated to June 25, 2019. Kraft Heinz’s June 2019 filing is the stronger source for the actual effective date.
That same-year elevation is why the two men can reasonably be compared as members of the 2019 class of new chief executives. It does not establish that they worked together, served on the same board or had a private relationship.
Miguel Patricio: from consumer brands to Kraft Heinz
Miguel Patricio is a Portuguese business executive whose career has centered on consumer products and brand management. His current AB InBev board biography says he studied Business Administration at Fundação Getulio Vargas in São Paulo and joined Ambev in 1998.
Before Kraft Heinz, his career included work at Philip Morris, Coca-Cola and Johnson & Johnson, followed by roughly two decades across Ambev and Anheuser-Busch InBev. His roles at the brewer included senior positions in North America and Asia Pacific as well as global marketing leadership.
That background made him an outside hire for Kraft Heinz rather than a leader promoted through the packaged-food company’s own ranks. When Kraft Heinz announced his appointment in 2019, Patricio said becoming CEO was a “privilege and an honor” and emphasized the need to respond to changing consumers and the food industry.
His actual tenure as chief executive began on June 25, 2019. He later added the position of board chair in 2022.
By 2023, another leadership transition was underway. Kraft Heinz said Carlos Abrams-Rivera would become chief executive effective January 1, 2024, while Patricio would move into the position of non-executive chair. The change is documented in the company’s August 2023 SEC filing.
Patricio’s role changed again in September 2025, when Kraft Heinz named him Executive Chair in connection with a planned corporate separation. That position lasted through the end of the year. A December 2025 Kraft Heinz filing documented his departure from the Executive Chair role as John T. Cahill took over as board chair.
The proposed separation did not continue on its original timetable. Kraft Heinz announced in February 2026 that work on the plan had been paused.
Patricio also did not remain on the Kraft Heinz board indefinitely. The company’s 2026 proxy statement said he would not stand for reelection at the annual meeting, and the May 2026 shareholder vote elected a new slate without him.
That matters because some biography pages still describe Patricio as a Kraft Heinz director. Those descriptions are stale.
His current public-company role is back at AB InBev. Shareholders approved his appointment to its board on April 29, 2026 for a four-year term, according to the company’s shareholder-meeting record.
Albert Bourla: a scientific route to Pfizer’s top job
Albert Bourla followed a different route to corporate leadership. Born in Thessaloniki, Greece, he trained as a veterinarian and earned both a Doctor of Veterinary Medicine degree and a Ph.D. in Biotechnology of Reproduction from Aristotle University of Thessaloniki.
Pfizer says Bourla joined the company in 1993 and spent more than two decades moving through positions in animal health, established pharmaceutical products, vaccines, oncology, consumer healthcare and other businesses before reaching the top of the organization.
A Pfizer board-election announcement from 2018 records both his scientific education and his long Pfizer career.
Bourla became Pfizer’s chief operating officer on January 1, 2018. One year later, he took over as CEO. In the succession announcement, he described himself as “humbled and privileged” by the appointment.
His authority expanded again on January 1, 2020, when he became chairman of Pfizer’s board while continuing as chief executive. Pfizer’s chairman succession announcement documents that change.
The COVID-19 pandemic became the most publicly visible chapter of his tenure. Pfizer worked with BioNTech on the COVID-19 vaccine that received U.S. emergency authorization in December 2020. That achievement belonged to the companies, their scientists, manufacturing teams and clinical partners rather than to Bourla alone, but his position as Pfizer’s CEO placed him at the center of the company’s response and made him a much more prominent public figure.
Pfizer’s post-pandemic period has brought a different set of challenges, including reduced demand for COVID-related products and renewed emphasis on areas such as oncology, internal medicine, vaccines and other pipeline priorities.
Bourla remains in charge. An August 12, 2026 SEC Form 4 identifies him as Pfizer’s “Chairman & CEO,” providing recent confirmation of his status.
Two different paths to the CEO office
The comparison between Patricio and Bourla is most useful when it focuses on how differently they reached senior leadership.
Patricio moved across several major consumer companies and built expertise in marketing, branding and international consumer markets. His career included multiple employers and geographic assignments before Kraft Heinz recruited him from outside the company.
Bourla, by contrast, spent the overwhelming majority of his career inside Pfizer. His route began with scientific training and animal health, then moved through progressively larger pharmaceutical businesses before he became COO and finally CEO.
Those paths produced two distinct executive profiles. Patricio’s career was built around consumer brands and cross-company experience. Bourla’s was built around scientific training and long-term advancement within a single pharmaceutical organization.
The similarity is the level they reached and the year they reached it, not a shared professional history.
Where are Miguel Patricio and Albert Bourla now?
As of October 2, 2026, Patricio is an AB InBev director representing the company’s main shareholders. His return to AB InBev’s board places him again at an organization where he spent much of his earlier career.
He is no longer a Kraft Heinz chief executive, chair or elected director. That is the main current-status correction readers should keep in mind when encountering older profiles.
Bourla remains Pfizer’s Chairman and CEO. His present role is supported by both Pfizer’s current leadership materials and 2026 SEC records.
Their trajectories have therefore diverged further since 2019: Patricio has moved from an operating CEO role into board-level governance, while Bourla continues to lead the same company whose top job he assumed at the start of that year.
Are Miguel Patricio and Albert Bourla related?
There is no public confirmation that Miguel Patricio and Albert Bourla are related.
Likewise, no shared employer, board membership or joint business venture between them is established in the corporate records that define their careers. Their documented overlap is the 2019 CEO cohort and the broader fact that both led major multinational companies during the same period.
Seeing their names together should therefore not be read as evidence of a family or business partnership. The more accurate explanation is simpler: they are two senior executives whose careers reached the CEO level in the same year through very different professional paths.
